More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors Jo-Anne H. Young, MD, Brent R. Logan,

Slides:

Advertisements

Similar presentations

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation Patrick.

Advertisements

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Topical Ruxolitinib Protects LGR5+ Stem Cells in the Hair Follicle and Ameliorates Skin Graft-Versus-Host Disease Shuichiro Takahashi, MD, Daigo Hashimoto,

Related PBSC Donors Age >60 Have High Rates of Baseline and Donation-Related Pain and Slow Recovery: First Report from the Related Donor Safety Study.

How to Treat MDS without Stem Cell Transplantation

The Effect of the Composition of Unrelated Donor Bone Marrow and Peripheral Blood Progenitor Cell Grafts on Transplantation Outcomes Nancy H. Collins,

A Survival Benefit for Reduced Intensity Allogeneic Transplants from Young Unrelated Donors Compared to Older Sibling Donors Depends on the Graft CD8.

Health-related Quality of Life of Bone Marrow versus Peripheral Blood Stem Cell Donors: A Prespecified Subgroup Analysis from a Phase III RCT—BMTCTN Protocol.

Randomized, Double-Blind, Placebo-Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Idiopathic Pneumonia.

FDG-PET Interpreted By Deauville Criteria Prior to Allogeneic Transplantation Predicts Outcomes in Patients with Relapsed or Refractory Hodgkin Lymphoma

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia Katerina Ancevski,

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Systematic Anti-Mold Prophylaxis Results in Very Low Incidence of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Pain, Donation-Related Symptoms and the Trajectory of Recovery in Children after Bone Marrow (BM) Donation Are Influenced By Age (Pre vs. Post-Puberty)

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia Mei-Jie.

Related PBSC Donors Experience Higher Levels of Pain and Donation-Related Symptoms and Less Complete Rates of Recovery Compared to Unrelated Donors:

CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival Mary.

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation Joseph Pidala, Claudio.

Jo-Anne H. Young, Brent R. Logan, Juan Wu, John R. Wingard, Daniel J

J. J. Nietfeld, Marcelo C. Pasquini, Brent R

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Jill C. Beck, John E. Wagner, Todd E. DeFor, Claudio G

Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302 Javier Bolaños-Meade, Juan Wu, Brent R. Logan,

Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized.

Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection Ron Mihelic,

Distinctions Between Effective and Ineffective AML-Specific Autologous Peripheral Blood (PB) Cytotoxic T-Lymphocytes (CTLs) Rohtesh S. Mehta, MD MPH.

John R. Wingard, M. D. , Alan K. Leahigh, Dennis Confer, M. D

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors with an Activating KIR Genotype Marcie Tomblyn,

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia Richard Mitchell, Todd Defor, John E. Wagner,

Graft-Versus-Host Disease Targets Granulosa Cell of Ovarian Follicle and Causes Infertility after Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase.

GVHD Prophylaxis with Post-Transplant High Dose Cyclophosphamide: Impact on Engraftment, Treatment-Related Mortality and Resource Utilization Nasheed.

Frederick R. Appelbaum, Claudio Anasetti, Joseph H

Infection Prevention - Visitors and the Best of Intentions

Similar Invasive Fungal Infection Rates and Survival after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Bone Marrow or.

Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.

Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.

Human Parainfluenza Virus Infection after Hematopoietic Stem Cell Transplantation: Risk Factors, Management, Mortality, and Changes over Time Celalettin.

Comparative Analysis: Trend of Infectious Complications in Cord Blood (CB) Versus Peripheral Blood (PB) and Bone Marrow (BM) Stem Cell Transplant (SCT)

Myeloid Derived Suppressor Cells (MDSC)-like Acute Myeloid Leukemia (AML) Cells Are Associated with Resistance to Cytotoxic Effects of Autologous (Auto)

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Outcomes of Second Unrelated Donor Cord Blood Transplants (UCBT) Performed in Children with Graft Failure of Autologous Recovery Following the First UCBT

Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation Patrick.

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.

HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category Ann Woolfrey, Stephanie J.

Biology of Blood and Marrow Transplantation

Systemic Toxoplasmosis Post Allogeneic Stem Cell Transplantation (Allo-SCT): Lessons Learned from HIV? Marie von Lilienfeld-Toal, MD, Maria Gilleece,

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Reduced Intensity Versus Myeloablative Conditioning Allogeneic HCT for Relapsed/Refractory Lymphoma: Applying Refined Disease Risk Index (DRI) to Improve.

Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.

Heather A. Himburg, PhD, Liman Zhao, Jenny Kan, John P. Chute, M.D.

Treatment versus Transplant for Challenging Hematologic Disorders

IL-8 Levels Early after Bone Marrow Transplant are Associated with Later Complications of Stem Cell Transplantation Nikhil Dole, Nathan Luebbering, Nicholas.

Reduced-Intensity Conditioning for Unrelated Donor Progenitor Cell Transplantation: Long-Term Follow-Up of the First 285 Reported to the National Marrow.

Classification of HLA-Matching for Retrospective Analysis of Unrelated Donor Transplantation: Revised Definitions to Predict Survival Daniel Weisdorf,

Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies Mary Eapen, Paul O'Donnell,

Mary Eapen Biology of Blood and Marrow Transplantation

In Memoriam: E. Donnall Thomas

Optimal Donor Selection: Beyond HLA

Radiation Disasters: Role of the BMT Team

Presentation transcript:

More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors Jo-Anne H. Young, MD, Brent R. Logan, PhD, Juan (Maggie) Wu, MS, John R. Wingard, MD, Daniel J. Weisdorf, MD, Cathryn Mudrick, MPH, Kristin Knust, MS, Mary M. Horowitz, MD, MS, Dennis L. Confer, MD, Claudio Anasetti, MD Biology of Blood and Marrow Transplantation Volume 21, Issue 2, Pages S49-S50 (February 2015) DOI: 10.1016/j.bbmt.2014.11.044 Copyright © 2015 Terms and Conditions

Fig 1 CumI of Overall Infxns by treatment arm. Biology of Blood and Marrow Transplantation 2015 21, S49-S50DOI: (10.1016/j.bbmt.2014.11.044) Copyright © 2015 Terms and Conditions

Fig 2 CumI of Bacterial Infxns by treatment arm. Biology of Blood and Marrow Transplantation 2015 21, S49-S50DOI: (10.1016/j.bbmt.2014.11.044) Copyright © 2015 Terms and Conditions